Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ami Maruyama"'
Autor:
Ami Maruyama, Yuzo Sato, Joji Nakayama, Junko Murai, Takamasa Ishikawa, Tomoyoshi Soga, Hideki Makinoshima
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Deoxyribonucleotide biosynthesis from ribonucleotides supports the growth of active cancer cells by producing building blocks for DNA. Although ribonucleotide reductase (RNR) is known to catalyze the rate-limiting step of de novo deoxyribonu
Externí odkaz:
https://doaj.org/article/e15465d288934f60aca475f9ca9bc802
Autor:
Yuzo Sato, Shiori Matsuda, Ami Maruyama, Joji Nakayama, Tomoyuki Miyashita, Hibiki Udagawa, Shigeki Umemura, Kazuyoshi Yanagihara, Atsushi Ochiai, Masaru Tomita, Tomoyoshi Soga, Katsuya Tsuchihara, Hideki Makinoshima
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS),
Externí odkaz:
https://doaj.org/article/ee31766fec794ef697c6af12fa10b995
Autor:
Katsuya Tsuchihara, Koichi Goto, Takehiko Sasaki, Hiroyasu Esumi, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii, Seiji Niho, Shingo Matsumoto, Sachiyo Mimaki, Hibiki Udagawa, Ami Maruyama, Hiroki Nakanishi, Ayako Suzuki, Shigeki Umemura, Hideki Makinoshima
Supplemental Experimental Procedures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b265538a4e1a4337c5c6c94fae8f1038
https://doi.org/10.1158/0008-5472.22417869
https://doi.org/10.1158/0008-5472.22417869
Autor:
Katsuya Tsuchihara, Koichi Goto, Takehiko Sasaki, Hiroyasu Esumi, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii, Seiji Niho, Shingo Matsumoto, Sachiyo Mimaki, Hibiki Udagawa, Ami Maruyama, Hiroki Nakanishi, Ayako Suzuki, Shigeki Umemura, Hideki Makinoshima
Supplementary figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445a0e475ded8c0d6c88e600fbc7642b
https://doi.org/10.1158/0008-5472.22417860
https://doi.org/10.1158/0008-5472.22417860
Autor:
Katsuya Tsuchihara, Koichi Goto, Takehiko Sasaki, Hiroyasu Esumi, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii, Seiji Niho, Shingo Matsumoto, Sachiyo Mimaki, Hibiki Udagawa, Ami Maruyama, Hiroki Nakanishi, Ayako Suzuki, Shigeki Umemura, Hideki Makinoshima
Supplementary Fig. S1. The mean baseline Levels of PIP3 (38:4) per mg tissue in xenograft models transplanted with SCLC cells Supplementary Fig. S2. Metabolic alteration in SCLC cells treated with gedatolisib in vitro and in vivo Supplementary Fig. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5916a3e558707fa4bb0a242d145d508e
https://doi.org/10.1158/0008-5472.22417863.v1
https://doi.org/10.1158/0008-5472.22417863.v1
Autor:
Katsuya Tsuchihara, Koichi Goto, Takehiko Sasaki, Hiroyasu Esumi, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii, Seiji Niho, Shingo Matsumoto, Sachiyo Mimaki, Hibiki Udagawa, Ami Maruyama, Hiroki Nakanishi, Ayako Suzuki, Shigeki Umemura, Hideki Makinoshima
Supplementary Table S1. The pathway classification of metabolites used for the MSEA Supplementary Table S2. Genetic profiles in 42 SCLC cell lines Supplementary Table S3. Quantitative phospho-peptide analysis in H1048 cells with or without Gedatolisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1174a1c3087ad33026c30ab96568f591
https://doi.org/10.1158/0008-5472.22417866.v1
https://doi.org/10.1158/0008-5472.22417866.v1
Autor:
Katsuya Tsuchihara, Koichi Goto, Takehiko Sasaki, Hiroyasu Esumi, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii, Seiji Niho, Shingo Matsumoto, Sachiyo Mimaki, Hibiki Udagawa, Ami Maruyama, Hiroki Nakanishi, Ayako Suzuki, Shigeki Umemura, Hideki Makinoshima
Comprehensive genomic analysis has revealed that the PI3K/AKT/mTOR pathway is a feasible therapeutic target in small-cell lung carcinoma (SCLC). However, biomarkers to identify patients likely to benefit from inhibitors of this pathway have not been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133bf576ebca7ebe64ef003e3e6c2f58
https://doi.org/10.1158/0008-5472.c.6509964.v1
https://doi.org/10.1158/0008-5472.c.6509964.v1
Autor:
Takamasa Ishikawa, Yuzo Sato, Tomoyoshi Soga, Junko Murai, Hideki Makinoshima, Joji Nakayama, Ami Maruyama
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Scientific Reports
Scientific Reports
Deoxyribonucleotide biosynthesis from ribonucleotides supports the growth of active cancer cells by producing building blocks for DNA. Although ribonucleotide reductase (RNR) is known to catalyze the rate-limiting step of de novo deoxyribonucleotide
Metastasis is responsible for approximately 90% of cancer-associated mortality and proceeds through multiple steps. Several herbal medicines are reported to inhibit primary tumor growth, but the suppressor effects of the medicines on metastasis progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cade6f8d93a0e499a553edf6891fd6a
https://doi.org/10.1101/2021.03.25.437098
https://doi.org/10.1101/2021.03.25.437098
Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance
Autor:
Hideki Makinoshima, Masahiro Tsuboi, Atsushi Ochiai, Yinghan Su, Genichiro Ishii, Shota Yamazaki, Ami Maruyama, Jun Suzuki, Koichi Goto
Publikováno v:
Biochemical and biophysical research communications. 526(1)
Collagen type I (Col I) is one of the major extracellular matrix proteins in the cancer tissue. Previously, we have reported that Col I induces epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance by mTOR activation throug